Close Menu

NEW YORK – German infectious disease diagnostics startup Noscendo said on Thursday that it has raised an undisclosed amount of funding in a Series A financing round.

Participants in the round included existing investors Wieland Capital and High-Tech Gründerfonds and new investors Earlybird, Paua Ventures, and JIH Family Office.

Noscendo plans to use the funding to expand its business, hiring a CSO and a chief operating officer and launching its Disqver bioinformatics platform for the detection of cell-free pathogen DNA in blood in Europe.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.